(TheNewswire)
VANCOUVER, BC / TheNewswire / April 19 , 202 2 / AREV Life Sciences GlobalCorp. (CSE:AREV) (OTC:AREVF)(“AREV” or the “Company” ) AREV Life SciencesGlobal Corporation announced today the appointment of Brian V.Elliott, B Comm to its Board of Directors.
In the pursuit of innovative global health solutions,AREV Life Sciences Global Corporation adds Brian V. Elliott , among its Board of Directors.
Brian V. Elliott is an international strategist andleader exhibiting over 35 years in Senior Management positions in thepharmaceutical industry and the health related public sectors. He hasprovided10 years of service with the Irish Government IndustrialDevelopment Authority in Ireland, France, and Lesotho.
Brian entered the pharmaceutical industry holding theposition of International Sales Director with Norton HealthcareGenerics based in Ireland and the UK directing their Ireland-basedmanufacturing operations. He assumed the position of Director ofJanssen Pharmaceutica NV with responsibility for China, andsubsequently was appointed International Trade Director, JanssenAfrica, Middle East, West Asia.
He was recruited by Belgian biotech companyTibotec-Virco NV, as Senior Vice President, Corporate Alliances andBusiness Development. Brian also served as CEO of Tibotec Virco,Ireland.
Brian V. Elliott established Axios InternationalConsultants Ltd in Ireland, and was Chairman of the organization for 5years during which he undertook many developing country health relatedprojects including:
-
United Nations Programme on HIV/AIDS (UNAIDS)negotiator with pharma industry on access to antiretrovirals, where heco-designed the UNAIDS Drug Access Initiative and established pilotprojects in Vietnam, Chile, Uganda, and Cote d’Ivoire.
-
Advisor to the Danish Government Overseas Aid Ministryon International HIV/AIDS policy.
-
The design and implementation of several global accessinitiatives including:
-
-
Bristol Myers Squibb - Secure the Future project inSouth Africa,
-
Abbott - Step Forward for Children project in Tanzaniaand Burkina Faso, Abbott
-
Gilead - Global Viread donation programme
-
Pfizer - diflucan donation project Pfizer
-
Roche- Blue Skies project in Southern Africa
-
Glaxo Wellcome- tiered pricing for developingcountries.
-
In 2008 Brian was appointed Executive Director of TheMedical Transparency Alliance (MeTA), an alliance of the Departmentfor International Development- UK, World Bank, and World HealthOrganization (WHO) aimed at increasing access to essential medicinesin 7 pilot countries (Peru, Jordan, Kyrgizstan, Uganda, Zambia, Ghanaand The Philippines). He also served as a member of the AffordableMedicine Facility for Malaria (AMFm) Expert Advisory Panel on reviewof the project evaluation process.
Recently, Brian works advising a number of majorpharmaceutical companies establishing programs to provide globalaccess to medicines working closely with Johnson & Johnson GlobalPublic Health Group and other multinational companies. These effortsinclude reporting to companies, agencies and foundations on criticalaspects of HIV/AIDS treatment in developing countries.
Projects in these areas include: working closely withIndian manufacturers of antiretroviral drugs to advocate with GlobalFund and PEPFAR to modify their procurement processes, reporting. forUnited Nations Industrial Development Organization (UNIDO), UNAIDS,and WHO on the security of supply of HIV/AIDS commodities, reviewingthe Appropriate Use Criteria program (AUC)/ UNIDO PharmaceuticalManufacturing Plan for Africa for WHO, and providing strategies forimplementation of the Pharmaceutical Manufacturing Plan for Africa forWHO/UNIDO.
Brian continues advising Johnson & Johnson GlobalPublic Health Group and several other international pharmaceuticalcompanies on the establishment of Global Access to Medicine programsin developing countries. He compiled the WHO Procurement and SupplyManagement (PSM) pro?le update, which updated the PSM profiles for85 countries enabling assessment of the deployment status of CD4 andVL technology.
He addressed the special UN Assembly meeting on thelooming crisis in HIV treatment and formed and advised a coalition of11 Indian Generic Pharmaceutical Manufacturers and led discussionsbetween them, the President’s Emergency Plan for AIDS Relief (PEPFAR), and The Global Fund to address the perceivedinequities in the procurement system for antiretrovirals in lower- andmiddle- income countries, the market dynamics, and risk of security ofsupply.
He is currently managing the establishment of clinicaltrials of 2 novel drug drugs to treat NCDs and 2 Covid vaccinecandidates in Kenya and advising governments in sub-SaharanAfrica.
Further, the Company is pleased to announce thatt he Company has issued 150,000 stock options toDirectors, Officers and Consultants of the Company at a price of $0.22for a period of 5 years from the issuance dated. These options willvest immediately.
For further information, contact Mike Withrow,arevlifesciences@gmail.com 778-929-6536. For more information visitwww.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO &Director
ABOUT AREV Life Sciences GlobalCorp.
AREV Life Sciences Global Corp. is a fully integrated,publicly traded, early-stage life science enterprise dedicated todelivering therapeutic interventions to public health throughextraction of unique compounds, discovery, innovation and successfulcollaborations. The company ’ s leadership drives discovery programs for clinicalcomplexities presented by malnutrition, viral infectious diseases andthe inflammatory response system. AREV is invested in commercialinnovations in phytomedicinal discoveries of small molecule antiviralsand for related neglected chronic co-morbidities and innovations humannutrition. AREV is dedicated to designing and delivering innovation inrational drug design, driven by presenting global epidemiologicalcharacteristics of multiple challenges to international human andanimal health. AREV is a member of both BIOTECanada and TheBiotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITSREGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITYFOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in policies ofthe CSE) accepts responsibility for the adequacy or accuracy of thisrelease. This news release may include forward-looking statements thatare subject to risks and uncertainties. All statements within, otherthan statements of historical fact, are to be considered forwardlooking. Although the Company believes the expectations expressed insuch forward-looking statements are based on reasonable assumptions,such statements are not guarantees of future performance and actualresults or developments may differ materially from those inforward-looking statements. Factors that could cause actual results todiffer materially from those in forward-looking statements includemarket prices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as requiredunder the applicable laws. This press release contains forward-lookingstatements. The use of any of the words "anticipate","continue", "estimate", "expect","may", "will", "project","should", "believe" and similar expressions areintended to identify forward-looking statements. Although theCompany believes that the expectations and assumptions on which theforward-looking statements are based are reasonable, undue relianceshould not be placed on the forward-looking statements because theCompany can give no assurance that they will prove to be correct.Since forward-looking statements address future events and conditions,by their very nature they involve inherent risks and uncertainties.These statements speak only as of the date of this press release.Actual results could differ materially from those currentlyanticipated due to a number of factors and risks various risk factorsdiscussed in the Company’ s Management ’sDiscussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2022 TheNewswire - All rights reserved.